Stanford University
Showing 601-620 of 956 Results
-
Oliver Nguyen
Ph.D. Student in Biology, admitted Autumn 2021
BioOliver (they/them) is a PhD Student at Stanford's Department of Biology and the Center for Conservation Biology. They are interested in the intersection of urban ecology and environmental justice and is working on a project that looks at inequity and residential segregation in multiple US cities and how that impacts human and avian communities. They are passionate about community-based research and using spatial data, web development, and data visualization to create tools for local communities/organizations combatting environmental injustice. They earned their BA in Biology and Environmental Studies at Tufts University and has previously worked at Point Blue Conservation Science, NASA DEVELOP, MGGG Redistricting Lab, and the Center for Health and Environmental Justice.
-
Phong Nguyen
DevOps Engineer, Digital Solutions, Graduate School of Business - Digital Solutions
Current Role at StanfordDatabase Administrator and Data Integration Analyst
-
Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology and, by courtesy, of Pediatrics and of Medicine (Immunology & Rheumatology)
Current Research and Scholarly InterestsWe have focused our research on the development of novel therapies and innovative assessment and diagnostic imaging technologies for retinal vascular and ocular inflammatory disorders, specifically diabetic retinopathy (DR), age-related macular degeneration (AMD) and uveitis. Building on our initial work describing the role of hypoxia and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and diabetic macular edema (DME), We have become interested in the biochemical mechanisms that would presumably lead to DME. During the past decade, our research has contributed to the body of evidences that defines the important role of anti-VEGF therapies in DME and AMD, as well as the role of the mTOR pathway and various interleukins in the pathogenesis of uveitis.
We have launched a productive and well-funded clinical research program while at the same time providing clinical care to patients with uveitis and retinal vascular diseases and fulfilling significant teaching and administrative assignments. We have established a number of key collaborators both within and outside the institutions. In addition, we have also established Center in Baltimore and now in Silicon Valley, which has excelled in conducting proof-of concept, early-phase multi-center clinical trials and studies, exploring the clinical disease manifestations and the efficacy of various pharmacologic agents in retinal, uveitic, and ocular inflammatory disorders.
